Welcome to LookChem.com Sign In|Join Free

CAS

  • or

42310-45-2

Post Buying Request

42310-45-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

42310-45-2 Usage

General Description

2,4-Diamino-5-pyrimidinemethanol, also known as daraprim, is a chemical compound used in the treatment of malaria and certain parasitic infections. It works by interfering with the enzyme dihydrofolate reductase, which is essential for the growth and survival of the parasites. This disruption leads to the inhibition of DNA synthesis and ultimately the death of the parasites. Daraprim is often used in combination with other medications to increase its effectiveness and reduce the risk of resistance. Although it is an important medication for the treatment of certain diseases, it has also been the subject of controversy due to its high cost and accessibility issues.

Check Digit Verification of cas no

The CAS Registry Mumber 42310-45-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,2,3,1 and 0 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 42310-45:
(7*4)+(6*2)+(5*3)+(4*1)+(3*0)+(2*4)+(1*5)=72
72 % 10 = 2
So 42310-45-2 is a valid CAS Registry Number.

42310-45-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name (2,4-diaminopyrimidin-5-yl)methanol

1.2 Other means of identification

Product number -
Other names 5-Pyrimidinemethanol,2,4-diamino

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:42310-45-2 SDS

42310-45-2Relevant articles and documents

Structure aided design of chimeric antibiotics

Karoli, Tomislav,Mamidyala, Sreeman K.,Zuegg, Johannes,Fry, Scott R.,Tee, Ernest H.L.,Bradford, Tanya A.,Madala, Praveen K.,Huang, Johnny X.,Ramu, Soumya,Butler, Mark S.,Cooper, Matthew A.

supporting information; experimental part, p. 2428 - 2433 (2012/05/19)

The rise of antibiotic resistance is of great clinical concern. One approach to reducing the development of resistance is to co-administer two or more antibiotics with different modes of action. However, it can be difficult to control the distribution and

Design, synthesis, biological evaluation and computational investigation of novel inhibitors of dihydrofolate reductase of opportunistic pathogens

Bag, Seema,Tawari, Nilesh R.,Degani, Mariam S.,Queener, Sherry F.

experimental part, p. 3187 - 3197 (2010/07/08)

The present work deals with design, synthesis and biological evaluation of novel, diverse compounds as potential inhibitors of dihydrofolate reductase (DHFR) from opportunistic microorganisms; Pneumocystis carinii (pc), Toxoplasma gondii (tg) and Mycobacterium avium (ma). A set of 14 structurally diverse compounds were designed with varying key pharmacophoric features of DHFR inhibitors, bulky distal substitutions and different bridges joining the distal part and 2,4-diaminopyrimidine nucleus. The designed compounds were synthesized and evaluated in enzyme assay against pc, tg and ma DHFR. The rat liver (rl) DHFR was used as mammalian standard. As the next logical step of the project, flexible molecular docking studies were carried out to predict the binding modes of these compounds in pcDHFR active site and the obtained docked poses were post processed using MM-GBSA protocol for prediction of relative binding affinity. The predicted binding modes were able to rationalize the experimental results in most cases. Of particular interest, both the docking scores and MM-GBSA predicted ΔGbind were able to distinguish between the active and low active compounds. Furthermore, good correlation coefficient of 0.797 was obtained between the IC50 values and MM-GBSA predicted ΔGbind. Taken together, the current work provides not only a novel scaffold for further optimization of DHFR inhibitors but also an understanding of the specific interactions of inhibitors with DHFR and structural modifications that improve selectivity.

Antibacterial pyrimidine compounds

-

, (2008/06/13)

-

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 42310-45-2